Breaking News: Congress Passes 2018 Farm Bill; Lots of Green Potential to Gain Big in this Uncertain Market
December 13 2018 - 7:30AM
Cannagreed.com News Commentary
While stocks have taken a beating due to trade concerns with
China and rising rates, there is green at the end of the tunnel!
With Congress approving the 2018 Farm Bill, stocks in the CBD space
are poised to benefit and should run counter to the current market
downward trends. The passage of the 2018 Farm Bill presents a
tremendous opportunity for the CBD sector to continue to grow while
the rest of the market shows significant volatility.
Cannabidiol, or CBD, is the non-psychoactive chemical compound
found in the hemp plant. The 2018 Farm Bill will nationally
legalize the cultivation and farming of that plant. This bill also
allows for the national legalization of CBD, lifting many barriers
that exist for full scale commercial acceptance of the compound.
“This is a watershed moment for the CBD industry,” said Brightfield
Group, a company that specializes in cannabis and CBD market
research, which projects that the medical and recreational CBD
market is expected to reach an estimated value of $22 billion by
2022.
Many companies have been positioning themselves to take
advantage of this huge, untapped market opportunity that the CBD
and Hemp space presents. These companies present an opportunity to
get in early and capitalize from expected passage of the Farm Bill
before it could be too late.
EnviroTechnologies International (OTC:ETII), a developer and
marketer of green, natural and organic products recently announced
the acquisition of CBD Health Co., a company that markets and sells
high quality and proprietary hemp-based, natural CBD health
products. Gaylord Karren, ETII’s CEO, commented, “We acquired CBD
Health Co. because our company was founded to use green and natural
products to make our environment safer and promote products that
improve our quality of life.” This acquisition came after the
Company’s launch of CBD Hemp Protein, which caters to the health
and sports markets. This product offers a high-quality,
eco-friendly compound that can support muscle gain, fat loss, and
peak performance. All of ETII’s products are poised for greater
distribution now that the Farm Bill has passed Congress.
Cronos Group (NASDAQ:CRON) the Canadian based cannabis producer
entered into a subscription agreement with tobacco company Altria
Group, Inc. Altria agreed to make an approximately $1.7 billion
equity investment in Cronos Group. The Shares issuable to Altria
pursuant to the Subscription Agreement will result in Altria
holding an approximately 45% ownership interest in Cronos Group.
“This strategic partnership provides Cronos Group with additional
financial resources, product development and commercialization
capabilities, and deep regulatory expertise to better position the
Company to compete, scale and lead the rapidly growing global
cannabis industry,” stated Cronos CEO Mike Gorenstein. Altria’s
investment in Cronos also positions the Company to capitalize off
the passage of the Farm Bill, as with Hemp now being a legal crop,
Altria can shift cultivation from its millions of acres of farms
from tobacco to Hemp.
GW Pharmaceuticals (OTC:GWPRF), the maker of Epidiolex, an
epilepsy drug that contains CBD. This is the first FDA-approved
drug made from the cannabis plant, and its approval was done in
tandem with the FDA reclassifying certain drugs containing CBD to
Schedule 5 drugs. Now that CBD is a legal substance, there
are expectations that the Company will be looking to develop other
CBD derived drugs. They could be the market front-runners for the
soon to be nascent CBD biopharma space.
Cannabis Sativa, Inc (OTC:CBDS), is a US based marketer and
manufacturer of cannabis & hemp products. The Company recently
announced that it had secured a patent for a CBD lozenge that helps
treat hypertension. This opens up a potentially huge medical
opportunity for the Company, as hypertension is the one of the
country’s biggest ailments, afflicting in some 7 out of 10
Americans in some form. With the passage of the Farm Bill, it could
potentially open the door for insurance companies to provide
reimbursement for prescriptions of this drug, potentially opening
up tens of millions of dollars in additional revenue.
American Premium Water Corporation (OTC:HIPH), the marketer and
distributor of LALPINA CBD, the first hydro-nano beverage on the
market, announced that its has formed a distribution partnership
with Upside Health’s product Ouchie, a pain management app and
platform targeting the over 120 million Americans who live with
chronic pain. This partnership will give the Company access to a
captive audience of consumers afflicted with pain whom are most
likely to benefit from CBD products. Now that CBD will be under FDA
oversight, there is reason to believe that it will be adapted by
more insurance providers as a bona fide treatment, which could
allow for companies like American Premium Water to generate revenue
from government subsidies.
For commentary inquiries, please contact:
info@cannagreed.com
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CG undertakes no
obligation to update such statements.
You should not rely on the information presented; you should do
independent research to form your own opinion and decision.
Information contained in our disseminated emails does not
constitute investment, legal or tax advice upon which you should
rely. The purchase of high-risk securities may result in the loss
of your entire investment. Advertisements received by you are not a
solicitation or recommendation to buy securities of the advertised
company. CG was not compensated by, (NYSE:ACB),
(OTCPK:CBDS),(OTC:HIPH), (OTCQB: GWPRF), (OTC:CVSI) or any
other company mentioned in this article.
Full Disclaimer: http://www.cannagreed.com/disclaimer/
Cronos (NASDAQ:CRON)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cronos (NASDAQ:CRON)
Historical Stock Chart
From Sep 2023 to Sep 2024